Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

A Natural Alternative Treatment for Urinary Tract Infections: Itxasol©, the Importance of the Formulation.

Tytuł:
A Natural Alternative Treatment for Urinary Tract Infections: Itxasol©, the Importance of the Formulation.
Autorzy:
Cela-López JM; Achucarro Basque Center for Neuroscience, Campus of Biscay, University of the Basque Country/Euskal Herriko Unibertsitatea, Parque Científico de la UPV/EHU, Edificio Sede, Barrio Sarriena, 48940 Leioa, Spain.
Camacho Roldán CJ; Achucarro Basque Center for Neuroscience, Campus of Biscay, University of the Basque Country/Euskal Herriko Unibertsitatea, Parque Científico de la UPV/EHU, Edificio Sede, Barrio Sarriena, 48940 Leioa, Spain.
Gómez-Lizarraga G; Achucarro Basque Center for Neuroscience, Campus of Biscay, University of the Basque Country/Euskal Herriko Unibertsitatea, Parque Científico de la UPV/EHU, Edificio Sede, Barrio Sarriena, 48940 Leioa, Spain.
Martínez V; Achucarro Basque Center for Neuroscience, Campus of Biscay, University of the Basque Country/Euskal Herriko Unibertsitatea, Parque Científico de la UPV/EHU, Edificio Sede, Barrio Sarriena, 48940 Leioa, Spain.
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2021 Jul 28; Vol. 26 (15). Date of Electronic Publication: 2021 Jul 28.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, c1995-
MeSH Terms:
Acetylcysteine/*therapeutic use
Arbutin/*therapeutic use
Biological Products/*therapeutic use
Umbelliferones/*therapeutic use
Urinary Tract Infections/*drug therapy
Acetylcysteine/chemistry ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/therapeutic use ; Anti-Inflammatory Agents/chemistry ; Anti-Inflammatory Agents/therapeutic use ; Antifungal Agents/chemistry ; Antifungal Agents/therapeutic use ; Arbutin/chemistry ; Biofilms/drug effects ; Biofilms/growth & development ; Biological Products/chemistry ; Biomimetic Materials/chemistry ; Biomimetic Materials/therapeutic use ; Candida/drug effects ; Candida/growth & development ; Candida/pathogenicity ; Drug Combinations ; Female ; Gram-Negative Bacteria/drug effects ; Gram-Negative Bacteria/growth & development ; Gram-Negative Bacteria/pathogenicity ; Gram-Positive Bacteria/drug effects ; Gram-Positive Bacteria/growth & development ; Gram-Positive Bacteria/pathogenicity ; Humans ; Male ; Microbial Sensitivity Tests ; Umbelliferones/chemistry ; Urinary Tract Infections/microbiology ; Urinary Tract Infections/pathology
References:
Molecules. 2020 Jan 13;25(2):. (PMID: 31941080)
Heliyon. 2021 May 12;7(5):e07021. (PMID: 34036196)
Front Microbiol. 2013 Mar 12;4:47. (PMID: 23487476)
Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2942-8. (PMID: 25339490)
J Urol. 2005 Apr;173(4):1281-7. (PMID: 15758783)
J Spinal Cord Med. 2018 Mar;41(2):132-141. (PMID: 29323625)
GMS Hyg Infect Control. 2019 Feb 18;14:Doc14. (PMID: 30993060)
Bioorg Med Chem Lett. 2014 Apr 1;24(7):1856-61. (PMID: 24641976)
Sci Rep. 2017 Jul 6;7(1):4783. (PMID: 28684849)
Respir Med. 2016 Aug;117:190-7. (PMID: 27492531)
Nat Rev Microbiol. 2015 May;13(5):269-84. (PMID: 25853778)
Cytotechnology. 2018 Aug;70(4):1261-1278. (PMID: 29696482)
Int J Hyperthermia. 2020;37(1):130-136. (PMID: 31986930)
Chin J Nat Med. 2019 May 20;17(5):346-354. (PMID: 31171269)
Environ Sci Pollut Res Int. 2021 Mar;28(9):11558-11571. (PMID: 33128149)
Phytomedicine. 2021 Feb;82:153466. (PMID: 33494001)
Biofilm. 2020 Jan 15;2:100019. (PMID: 33447805)
J Fungi (Basel). 2017 Mar 22;3(1):. (PMID: 29371534)
Nat Prod Res. 2020 Aug;34(16):2354-2357. (PMID: 30417709)
J Infect Dis. 2000 Oct;182(4):1177-82. (PMID: 10979915)
Cancers (Basel). 2021 Mar 29;13(7):. (PMID: 33805488)
Eur Urol. 2020 Oct;78(4):540-543. (PMID: 32660748)
Am J Epidemiol. 2000 Jun 15;151(12):1194-205. (PMID: 10905532)
Microbiol Spectr. 2016 Dec;4(6):. (PMID: 28087935)
J Infect Dis. 1982 Nov;146(5):579-83. (PMID: 7130747)
Molecules. 2018 Dec 13;23(12):. (PMID: 30551603)
BMC Complement Altern Med. 2018 Jul 3;18(1):203. (PMID: 29970072)
Prz Menopauzalny. 2021 Apr;20(1):40-47. (PMID: 33935619)
Future Med Chem. 2015;7(4):493-512. (PMID: 25875875)
Eur J Pharm Biopharm. 2020 Dec;157:200-210. (PMID: 33222771)
Pathogens. 2014 Jun 18;3(2):473-98. (PMID: 25437810)
Can Urol Assoc J. 2014 Sep;8(9-10):E681-7. (PMID: 25408807)
Gen Pharmacol. 1996 Oct;27(7):1237-40. (PMID: 8981074)
N Engl J Med. 1996 Aug 15;335(7):468-74. (PMID: 8672152)
World J Urol. 2014 Feb;32(1):79-84. (PMID: 23633128)
Front Microbiol. 2021 Apr 30;12:638609. (PMID: 33995297)
Cochrane Database Syst Rev. 2004;(3):CD001209. (PMID: 15266443)
Antibiotics (Basel). 2021 Apr 01;10(4):. (PMID: 33915821)
Springerplus. 2013 Nov 28;2:639. (PMID: 24349947)
Antibiotics (Basel). 2021 Apr 10;10(4):. (PMID: 33920199)
Front Microbiol. 2012 Jan 19;3:9. (PMID: 22294983)
Am J Med. 2003 Oct 15;115(6):506-7. (PMID: 14563511)
J Clin Pharmacol. 2002 Aug;42(8):920-7. (PMID: 12162475)
J Microbiol. 2016 Apr;54(4):322-9. (PMID: 27033208)
Microb Pathog. 2020 Jul;144:104184. (PMID: 32304793)
Front Cell Infect Microbiol. 2019 Jan 04;8:445. (PMID: 30662877)
Front Microbiol. 2017 Aug 15;8:1566. (PMID: 28861072)
Infect Dis Clin North Am. 2014 Mar;28(1):1-13. (PMID: 24484571)
Microb Drug Resist. 2017 Sep;23(6):771-780. (PMID: 28118088)
Microorganisms. 2020 Jun 30;8(7):. (PMID: 32629850)
Int J Antimicrob Agents. 2006 Aug;28 Suppl 1:S42-8. (PMID: 16829049)
Urology. 2008 Jul;72(1):37-41; discussion 41. (PMID: 18342928)
Adv Chronic Kidney Dis. 2020 Jan;27(1):31-37. (PMID: 32146999)
Phytomedicine. 2014 Jul-Aug;21(8-9):1037-42. (PMID: 24837471)
BMJ Sex Reprod Health. 2021 Jul;47(3):e12. (PMID: 32868337)
Inflammation. 2019 Jun;42(3):1103-1116. (PMID: 30741365)
J Pharm Pharmacol. 2017 Oct;69(10):1253-1264. (PMID: 28675434)
J Natl Compr Canc Netw. 2013 Apr 1;11(4):446-75. (PMID: 23584347)
Appl Biochem Biotechnol. 2019 Dec;189(4):1291-1303. (PMID: 31254228)
Planta Med. 1979 Mar;35(3):253-61. (PMID: 432304)
J Thorac Dis. 2018 Jan;10(1):212-218. (PMID: 29600051)
Clin Infect Dis. 2012 Feb 1;54(3):340-6. (PMID: 22100577)
Clin Infect Dis. 2011 Mar 1;52(5):e103-20. (PMID: 21292654)
FEMS Microbiol Rev. 2017 May 1;41(3):276-301. (PMID: 28369412)
N Engl J Med. 2016 Jun 2;374(22):2191-2. (PMID: 27248643)
BMC Complement Altern Med. 2013 Oct 20;13:273. (PMID: 24138888)
Crit Care. 2014 Nov 21;18(6):596. (PMID: 25412897)
J Food Sci Technol. 2015 Jun;52(6):3402-11. (PMID: 26028721)
Ann Intern Med. 2008 Feb 19;148(4):284-94. (PMID: 18283206)
Free Radic Res. 2018 Jul;52(7):751-762. (PMID: 29742938)
Acta Cir Bras. 2020 Oct 16;35(9):e202000905. (PMID: 33084735)
Fitoterapia. 2012 Jan;83(1):230-3. (PMID: 22088496)
Int J Mol Sci. 2021 Jan 17;22(2):. (PMID: 33477393)
Biomed Pharmacother. 2020 Sep;129:110432. (PMID: 32768935)
Foodborne Pathog Dis. 2011 Jan;8(1):149-57. (PMID: 21034269)
Curr Top Med Chem. 2017;17(29):3219-3231. (PMID: 29243577)
J Diabetes Res. 2020 Jan 27;2020:9589507. (PMID: 32083136)
Expert Opin Ther Pat. 2017 Feb;27(2):179-189. (PMID: 27828733)
Chronobiol Int. 2015;32(9):1223-32. (PMID: 26506922)
J Infect Chemother. 2012 Aug;18(4):479-84. (PMID: 22249689)
Lancet. 1995 May 6;345(8958):1187. (PMID: 7723580)
J R Soc Interface. 2006 Aug 22;3(9):471-82. (PMID: 16849244)
Prim Care. 2018 Sep;45(3):455-466. (PMID: 30115334)
Lancet Infect Dis. 2012 Mar;12(3):249-53. (PMID: 22101066)
Mol Microbiol. 2005 Jan;55(2):441-55. (PMID: 15659162)
J Mycol Med. 2019 Apr;29(1):28-34. (PMID: 30606640)
J Infect Chemother. 2016 Apr;22(4):200-8. (PMID: 26867795)
Urol Clin North Am. 2015 Nov;42(4):561-8. (PMID: 26475952)
Climacteric. 2019 Jun;22(3):242-249. (PMID: 30624087)
J Microbiol Biotechnol. 2010 Aug;20(8):1204-9. (PMID: 20798583)
Biotechnol Rep (Amst). 2021 Mar 26;30:e00613. (PMID: 33996521)
J Family Med Prim Care. 2017 Apr-Jun;6(2):360-365. (PMID: 29302548)
Microbiol Spectr. 2016 Oct;4(5):. (PMID: 27780014)
Biomed Pharmacother. 2017 Aug;92:661-671. (PMID: 28586740)
Front Cell Infect Microbiol. 2019 Oct 18;9:357. (PMID: 31681633)
Nat Rev Urol. 2010 Dec;7(12):653-60. (PMID: 21139641)
Eur J Med Chem. 2020 Dec 15;208:112829. (PMID: 33002736)
PLoS One. 2018 Oct 1;13(10):e0203941. (PMID: 30273348)
Lancet Infect Dis. 2015 Dec;15(12):1429-37. (PMID: 26482597)
P T. 2015 Apr;40(4):277-83. (PMID: 25859123)
Urol Oncol. 2020 Mar;38(3):75.e9-75.e14. (PMID: 31956079)
Braz J Microbiol. 2018 Jan - Mar;49(1):184-188. (PMID: 28916389)
Mycoses. 2011 Sep;54(5):e569-71. (PMID: 21605187)
GMS Infect Dis. 2021 May 27;9:Doc03. (PMID: 34113535)
J Chemother. 2018 Apr;30(2):107-114. (PMID: 29078739)
Biomed Pharmacother. 2018 Jun;102:392-402. (PMID: 29573618)
Mol Immunol. 2019 Apr;108:56-67. (PMID: 30784763)
Gen Pharmacol. 1996 Jun;27(4):713-22. (PMID: 8853310)
J Pathog. 2016;2016:1590952. (PMID: 27127655)
Vet Dermatol. 2016 Jun;27(3):188-e47. (PMID: 27122224)
Pharmacol Rep. 2017 Dec;69(6):1263-1269. (PMID: 29128808)
JAMA. 2020 Nov 17;324(19):1980-1991. (PMID: 33201207)
J Ethnopharmacol. 2021 Jan 30;265:113210. (PMID: 32795501)
Biomater Sci. 2020 Jul 28;8(15):4095-4108. (PMID: 32555809)
Clin Infect Dis. 2013 Sep;57(5):719-24. (PMID: 23645845)
Lung Cancer. 2004 Mar;43(3):275-83. (PMID: 15165085)
Biochim Biophys Acta. 2013 Aug;1830(8):4117-29. (PMID: 23618697)
Contributed Indexing:
Keywords: N-acetyl l-cysteine; arbutin; umbelliferon; urinary tract infections
Substance Nomenclature:
0 (Anti-Bacterial Agents)
0 (Anti-Inflammatory Agents)
0 (Antifungal Agents)
0 (Biological Products)
0 (Drug Combinations)
0 (Umbelliferones)
60Z60NTL4G (7-hydroxycoumarin)
C5INA23HXF (Arbutin)
WYQ7N0BPYC (Acetylcysteine)
Entry Date(s):
Date Created: 20210807 Date Completed: 20210920 Latest Revision: 20210920
Update Code:
20240105
PubMed Central ID:
PMC8348710
DOI:
10.3390/molecules26154564
PMID:
34361723
Czasopismo naukowe
Genito-urinary tract infections have a high incidence in the general population, being more prevalent among women than men. These diseases are usually treated with antibiotics, but very frequently, they are recurrent and lead to the creation of resistance and are associated with increased morbidity and mortality. For this reason, it is necessary to develop new compounds for their treatment. In this work, our objective is to review the characteristics of the compounds of a new formulation called Itxasol© that is prescribed as an adjuvant for the treatment of UTIs and composed of β-arbutin, umbelliferon and n-acetyl cysteine. This formulation, based on biomimetic principles, makes Itxasol© a broad-spectrum antibiotic with bactericidal, bacteriostatic and antifungal properties that is capable of destroying the biofilm and stopping its formation. It also acts as an anti-inflammatory agent, without the adverse effects associated with the recurrent use of antibiotics that leads to renal nephrotoxicity and other side effects. All these characteristics make Itxasol© an ideal candidate for the treatment of UTIs since it behaves like an antibiotic and with better characteristics than other adjuvants, such as D-mannose and cranberry extracts.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies